Prostate cancer treatment Erleada

Janssen’s prostate cancer treatment Erleada receives EC licence 

Johnson & Johnson announce that the European Commission (EC) has licensed prostate cancer treatment Erleada for non-metastatic castration-resistant prostate cancer (nmCRPC) The licence is based on...
Seqirus receive approval for quadrivalent influenza vaccine

Seqirus receive approval for quadrivalent influenza vaccine

Seqirus announces that the European Commission has issued marketing approval for its new cell-based quadrivalent influenza vaccine, FLUCELVAX® TETRA▼ This will be the first cell-based...
first cohort of medica writers from Ashfield's Allegro

Ashfield’s first cohort of medical writers graduate from Allegro

One year on from launch, Ashfield Healthcare Communications has announced the graduation of the first cohort of medical writers from its innovative training programme,...
Digital GP service expands.

Digital GP service broadens reach

Following its launch to corporate health insurance customers, the Aviva Digital GP service (provided by Aviva in collaboration with Now Healthcare Group) has broadened...
NICE rejects Novartis Aimovig for prevention of migraine

NICE rejects Novartis Aimovig for prevention of migraine

NICE rejects Novartis Aimovig for prevention of migraine in draft guidance published today. Novartis and NICE have both expressed disappointment, saying they will work...
oral chemotherapy drug in clinical trials

CRUK, NIHR and Athenex trial innovative oral chemotherapy 

The experimental oral chemotherapy drug Oraxol is moving into early phase clinical trials.  This is as part of a new partnership between Athenex, Cancer Research...
FDA breakthrough therapy designation for crizanlizumab

FDA breakthrough therapy designation for crizanlizumab

Novartis announces that the FDA has granted breakthrough therapy designation for crizanlizumab for the prevention of VOCs in patients with sickle cell disease (SCD). The...
Amryt announces the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 for EB.

Amryt announces trial interim efficacy analysis results for EB treatment

Amryt has announced the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 as a potential treatment...
Janssen have completed an EMA application for Stelara

Janssen submit EMA application for Stelara ® in ulcerative colitis

Janssen have completed an EMA application for Stelara ® for a form of inflammatory bowel disease (IBD) - ulcerative colitis  The Janssen Pharmaceutical Companies of Johnson...

Bristol-Myers Squibb & Celgene Corporation announce a definitive merger agreement

Bristol-Myers Squibb Company and Celgene Corporation have announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene...

Latest articles

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer.  AbbVie, a research-based global biopharmaceutical company,...
Star Europe reports positive client and candidate feedback.

Star Europe’s Amsterdam office off to positive start

Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
ORKAMBI® for cystic fibrosis

EC approves Vertex’s ORKAMBI® for cystic fibrosis patients

Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients.  The European Commission has granted approval...